FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Valeo Pharma Inc. Stock AnalysisComprehensive stock analysis for Valeo Pharma Inc. (VPHIF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisVPHIF
VPHIF
Valeo Pharma Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
VPHIF
Home🔹Stocks🔹Valeo Pharma Inc.

Valeo Pharma Inc.

VPHIF•OTC

Valeo Pharma Inc.

VPHIF•OTC
Market cap
$9.87K
Sentiment

Your view on VPHIF

Mkt Cap
$9.87K
Sentiment
Your view
VPHIF
Valeo Pharma Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
VPHIF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Valeo Pharma Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Kyle Steiger
Headquarters
16667 Hymus Boulevard, Kirkland, QC, CA
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Kyle Steiger
Headquarters
16667 Hymus Boulevard, Kirkland, QC, CA
Description

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News